Q-omics provides the consensus-scored ZNF660 profile across patient tissues and cancer cell-line models. ZNF660 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ZNF660 is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, ZNF660 RNA expression shows 21,149 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight SCLC, LUAD, and PDAC as cancer lineages where ZNF660 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF660 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF660 survival associations across molecular data types. ZNF660 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF660 RNA expression–survival associations across cancer types. High ZNF660 expression shows unfavorable associations in ACC, STAD, CESC and ESCA, but favorable associations in SCLC and HNSC. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for ZNF660 RNA expression.
This table summarizes ZNF660 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF660. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF660 shows lower tumor expression in LUAD, LUSC, THCA, KICH, BRCA and UCEC. The LUAD box plot shows higher ZNF660 RNA expression in normal versus tumor tissue (log2 FC = −0.893, t-test p < 0.001).
This table shows molecular features associated with ZNF660 in patient tissues and cancer cell lines. In patient samples, ZNF660 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF660 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LUNG_SCLC.
